Access to distal airway samples to assess respiratory diseases is not straightforward and requires invasive procedures such as bronchoscopy and bronchoalveolar lavage. The particles in exhaled air (PExA) device provides a non-invasive means of assessing small airways; it captures distal airway particles (PEx) sized around 0.5–7 μm and contains particles of respiratory tract lining fluid (RTLF) that originate during airway closure and opening. The PExA device can count particles and measure particle mass according to their size. The PEx particles can be analysed for metabolites on various analytical platforms to quantitatively measure targeted and untargeted lung specific markers of inflammation. As such, the measurement of distal airway components may help to evaluate acute and chronic inflammatory conditions such as asthma, chronic obstructive pulmonary disease, acute respiratory distress syndrome, and more recently, acute viral infections such as COVID-19. PExA may provide an alternative to traditional methods of airway sampling, such as induced sputum, tracheal aspirate, or bronchoalveolar lavage. The measurement of specific biomarkers of airway inflammation obtained directly from the RTLF by PExA enables a more accurate and comprehensive understanding of pathophysiological changes at the molecular level in patients with acute and chronic lung diseases.

Acute and chronic respiratory diseases impose a significant economic and health burden. Distal small airway assessment requires invasive procedures such as a bronchoscopy and bronchoalveolar lavage. The Particles in Exhaled Air (PExA) device provides a non-invasive means of assessing small airways; it captures distal airway particles sized around 0.5-7m and contains particles of respiratory tract lining fluid (RTLF) that originate during airway closure and opening. The PExA device can measure particle count and mass according to particle size. Subsequent capture of particles in a thin membrane enables application of various analytical methods to assess a broad range of biomolecules including phospholipids, proteins, inflammatory profile, and other metabolites to characterise inflammation and diseases processes such as asthma, chronic obstructive pulmonary disease, acute respiratory distress syndrome, lung cancer, and more recently acute infections such as COVID-19. PExA analysis provides a promising alternative to traditional investigative methods in the assessment, diagnosis, and management of respiratory conditions. By evaluating specific biomarkers in the RTLF associated with airway inflammation, PExA may offer a more accurate and comprehensive understanding of the molecular-level changes in the small airways of patients with acute and chronic lung diseases.

Rapid point of care assessment of pulmonary surfactant composition by measuring the lecithin/sphingomyelin (L/S) ratio could improve management of patients with neonatal respiratory distress syndrome (nRDS). Attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) offers a practical route to making such measurements, but the influence of the sample solvent prior to drying on measurement repeatability is poorly understood. We compare films dried from dichloromethane (DCM) and water (AQ) solvents (DCM-dry route vs. AQ-dry route) by ATR-FTIR and show that spectra from the AQ-dry route increased the signal-to-noise ratio (SNR) of a representative (2920 cm⁻¹) absorption peak for the mixture from 20.13 to 128.20 and for human endotracheal aspirate (ETA) from 6.33 to 8.13. A mixed nested analysis of variance (ANOVA) showed that drying route accounted for 89.52% of mixture peak height variance and reduced percent relative standard deviation (%RSD) from 23.5% to 16.2%, corroborated by multivariate analysis for ETA. We further demonstrate that partial least squares regression (PLSR) models trained on AQ-dry mixture spectra predicted L/S (R² = 0.91; root mean square error (RMSE) = 0.31) with 95% prediction interval grey-zone interpretation around L/S = 2.2, complemented by a receiver operating characteristic area under the curve (ROC-AUC) of 0.978.